NeuroPace (NPCE) Q1 2026 earnings review
The Pivot Pays Off: Gross Margins Explode as DIXI Exits
NeuroPace's Q1 2026 results prove that management's strategic decision to terminate the low-margin DIXI distribution agreement was exactly the right move. While optical total revenue decelerated sequentially due to the DIXI phase-out, the underlying core business is thriving. Core RNS revenue grew nearly 20% YoY, and Non-GAAP gross margin rocketed to an impressive 82.5%. The company is officially a high-margin, pure-play neuromodulation platform. However, the clock is still ticking on profitability, with a $6.7M net loss and $59M in debt requiring close monitoring as they push toward cash flow breakeven.
🐂 Bull Case
By eliminating the ~50% gross margin DIXI business, overall Non-GAAP gross margins immediately expanded to 82.5%. This creates immense operating leverage for every incremental RNS system sold.
Despite the total revenue noise, underlying core RNS revenue grew 19.5% YoY, driven by all-time highs in active prescribers, accounts, and patient pipelines.
🐻 Bear Case
The company holds $54.8M in cash against $59M in long-term debt. Even with improved EBITDA, bridging the gap to free cash flow positive before refinancing remains a crucial hurdle.
Because they are filling a $15.5M annual DIXI revenue hole, total reported YoY revenue growth for 2026 will appear virtually flat, which could pressure valuation multiples if the market misinterprets the dynamic.
⚖️ Verdict: 🟢
Bullish. The fundamental quality of NeuroPace's earnings has drastically improved. Swapping empty, low-margin distribution revenue for high-margin core device growth creates a much more defensible and scalable business model.
Key Themes
Gross Margin Profile Upgrade Completed
The transition is complete: NeuroPace is now a pure-play RNS company. DIXI revenue shrank to an immaterial $65k (down from $4.2M a year ago). Consequently, Non-GAAP gross margin accelerated from 77.0% to 82.5%. This step-change in profitability structurally changes the company's unit economics and drastically lowers the revenue threshold required for cash flow breakeven.
Core RNS Growth Remains Highly Stable
Underlying RNS System sales hit $21.7M, accelerating to 19.5% YoY growth. Management achieved new all-time highs in active prescribers, accounts, and patient pipelines, proving that clinical adoption of the therapy within Level 4 centers is compounding predictably, entirely independent of legacy distribution channels.
AI and Next-Gen Platform Investment
NeuroPace is shifting R&D focus from heavy clinical trials to AI-enabled tools and its next-generation platform. Although total R&D spend slightly decreased YoY (from $6.6M to $6.5M Non-GAAP), the composition shifted toward personnel developing data-driven, proprietary software. This technological innovation reinforces their 'data moat'—leveraging over 22 million recorded brain events to deliver personalized therapy.
Optical Sequential Revenue Deceleration
While the core business narrative is strong, the headline total revenue fell sequentially from $26.6M in 25Q4 to $22.1M in 26Q1. Though fully expected due to the planned DIXI exit, this data point completely masks the underlying growth and requires investors to heavily adjust their models to uncover the real operational momentum. Furthermore, overall sales will be effectively flat YoY for all of FY26.
Sales & Marketing Expense Outpacing Core Growth
Non-GAAP Sales and Marketing expense (excluding DIXI) grew to $11.0M, a 14.5% YoY increase. This represents 50% of total revenue. Management cited direct-to-consumer marketing and commercial scaling as the cause. For a company attempting to rein in cash burn, allowing S&M to expand at this rate demands scrutiny, especially when overall market access (macro environment) for medical devices remains highly competitive.
Cash Runway and Debt Overhang
Cash, equivalents, and short-term investments dwindled to $54.8M (down from $61.2M sequentially), translating to a ~$6.4M quarterly burn rate. Standing opposite to this is $59.0M in long-term debt. While Adjusted EBITDA losses are narrowing (-$3.3M this quarter), the margin for error in reaching sustained profitability before needing a capital raise is narrowing.
Regulatory Timeline: The NAUTILUS Catalyst
The company completed the FDA mid-cycle review for the NAUTILUS PMA-Supplement on schedule. This Idiopathic Generalized Epilepsy (IGE) indication expansion is the single largest binary event for the stock, with a potential approval slated for mid-2026. Given previous data showed an 80%+ reduction in generalized tonic-clonic seizures, approval would significantly expand the Total Addressable Market.
Other KPIs
Accelerating improvement. Improved by $0.8M compared to the $4.1M loss in Q1 2025. This metric is the clearest indicator of operating leverage; the explosive growth in gross margins directly mitigated the increased commercial spend, pushing the company closer to its breakeven goal.
Stable YoY. Compared to a $6.6M loss in the prior year. The difference between the improving EBITDA and the static Net Loss is largely driven by continuous heavy stock-based compensation (totaling over $2.2M) and interest expenses from their $59M debt load.
Guidance
Accelerating slightly vs prior guidance. Management raised the floor and ceiling from the previous $98-$100M range. Importantly, this implies roughly 0% YoY growth on a reported basis (FY25 was ~$100M), but mathematically implies 21% to 23% growth in the underlying RNS core business after adjusting for the massive $15.5M DIXI headwind.
Stable. The reiterated guidance signals that the 82.5% achieved in Q1 is not a fluke but the new structural baseline for the company as a pure-play manufacturer.
Accelerating. Raised from previous guidance of ($9.0) to ($10.0) million. The $0.5M improvement directly flows from the increased revenue guide and firm expense control outside of commercial scaling.
Key Questions
S&M Expense Ramping
With Non-GAAP Sales and Marketing expense rising nearly 15% YoY, what specific ROI metrics are you tracking on Direct-to-Consumer marketing, and at what point does this line item gain operating leverage?
NAUTILUS FDA Dialogue
Following the FDA mid-cycle review for NAUTILUS, were there any specific requests for additional data cuts or post-market commitments regarding the primary endpoint miss, or is the agency comfortable leaning purely on the secondary endpoints?
Cash Runway and Refinancing
You exited the quarter with $54.8M in cash and $59M in debt. Given the ~$6.4M quarterly burn rate, at what specific timeframe do you plan to address the capital structure to ensure uninterrupted funding to cash flow breakeven?